ConvaTec Executes Share Buyback in $300 Million Program

An update from ConvaTec ( (GB:CTEC) ) is now available.

ConvaTec Group PLC has executed a share buyback as part of its $300 million program, purchasing 633,625 ordinary shares through UBS AG London Branch. The shares, bought at an average price of 241.51 pence, will be held in treasury, affecting the company’s total voting rights and potentially impacting shareholder interests.

The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.27 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.

Spark’s Take on GB:CTEC Stock

According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.

ConvaTec’s overall stock score reflects its strong financial performance, which is the most significant factor. The company’s robust revenue growth, profitability, and cash flow management are key strengths. However, technical analysis indicates mixed signals, and the valuation suggests the stock may be overvalued, which could limit future gains. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on GB:CTEC stock, click here.

More about ConvaTec

ConvaTec Group PLC operates in the medical products and technologies industry, focusing on providing solutions for advanced wound care, ostomy care, continence and critical care, and infusion care. The company is known for its innovative healthcare products aimed at improving the lives of patients and healthcare providers globally.

Average Trading Volume: 7,807,475

Technical Sentiment Signal: Buy

Current Market Cap: £4.79B

See more insights into CTEC stock on TipRanks’ Stock Analysis page.